Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8 + T Cell Exhaustion Marker Expression
Year: 2017
Type: article
Study design: Observational Study
Abstract: In untreated HIV infection, CD8+ T cell exhaustion (i.e., decreased proliferative and effector capacity) is associated with high levels of expression of coinhibitory receptors, including PD-1, T cell immunoreceptor with Ig and ITIM domains (TIGIT), CD160, and 2B4. This is evident for both HIV-specific and non-HIV-specific CD8+ T cells. Antiretroviral therapy (ART) initiated during chronic infection decreases but may not completely normalize the expression of such “exhaustion markers.” Compared to initiation of ART later in the course of disease, initiation soon after infection reduces some parameters of chronic inflammation and adaptive immune dysfunction. However, it is not known if Early ART (e.g., initiated within the first 6 months after HIV infection) versus Delayed ART (e.g., initiated during chronic infection) preferentially reduces expression of exhaustion markers. We evaluated exhaustion marker expression on subsets of circulating effector and memory CD8+ T cells at longitudinal pre- and post-ART (2 and 5 years on ART) time points from n = 19 (Early ART) and n = 23 (Delayed ART) individuals. Before ART, TIGIT and CD160 were expressed on a statistically significantly higher proportion of effector and transitional memory cells from individuals in the Delayed ART group: the timing of ART initiation, however, did not consistently affect the expression of the exhaustion markers once viral suppression was achieved. Understanding which factors do and do not regulate aspects of CD8+ T cell exhaustion, including the expression of exhaustion markers, is critical to inform the rational design of CD8+ T cell-based therapies to treat HIV, for which CD8+ T cell exhaustion remains an important barrier to efficacy.
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Funders: Bill and Melinda Gates Foundation, amfAR, The Foundation for AIDS Research, Department of Science and Technology, Republic of the Philippines, National Institutes of Health, University of California, San Francisco, National Institute of Allergy and Infectious Diseases, National Center for Research Resources, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G1066646890, G1531094742, G1579526946, Clinical and Translational Science Institute, Impact of HIV-associated inflammation on disease, Determinants of Functional Immune Defects in Treated HIV Infection and Aging, G3181090803, DARE: Delaney AIDS Research Enterprise to find a cure., University of California San Francisco - to expand the existing specimen and data repository created by the Consortium for the Performance and Evaluation of HIV Incidence Assays (CEPHIA), G758528517, G8796610432, G9000058261, G9000078127, G9000081321, G9000100957, G9000219764, G97119092
OpenAlex ID: W2982328647
